Japan’s Otsuka Pharmaceutical (TYO: 4768) has sold commercialization rights to Netherlands-incorporated Mylan (Nasdaq: MYL) for the multidrug-resistant tuberculosis drug Deltyba (delamanid).
Mylan will start marketing the product in India and South Africa, high burden countries for the disease, with over 150,000 estimated new cases per year. While the drug is approved in India, registration is currently pending in South Africa.
The company expects to further exercise exclusive commercial rights and registration responsibilities in additional countries where Otsuka does not have a commercial presence.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze